Finoriq research workspace
Adicet Bio, Inc. (ACET) Company Overview
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T. Review ACET filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
- Company
- Adicet Bio, Inc. (ACET)
- Ticker
- ACET
- Market Cap
- $74.7M
- Latest Price
- $7.99
- Industry
- Biotech & Pharma
Adicet Bio, Inc. (ACET) Current Valuation Metrics
Static valuation preview for Adicet Bio, Inc. (ACET). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -129.2% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -108.4% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.6x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.